Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Petrobras
Petrobras is producing more oil at a lower cost, and it's not even trying. Q1 2026 results came in with record output, a record utilization factor, and a record S10 diesel yield. The company is now ch...
- Q1 2026 production hit 2.58 million barrels per day, with April setting a new monthly record of 2.73 million barrels per day, a 30% increase over 2024 levels.
- Petrobras is adding 180,000 barrels per day from four FPSO rigs, including the recently accelerated launch of P-79, which came online three months ahead of schedule.
- Refining utilization reached 97.4% in Q1, surpassing 100% in April, the highest level since 2014, driven by operational efficiency and increased processing capacity.
- +8 more takeaways
PACS Group Q1 2026 Earnings Call - Adjusted EBITDA Beats by $50M, Guidance Raised as Organic Growth Accelerates
PACS Group delivered a forceful start to 2026, driving revenue up 11% to $1.42 billion and Adjusted EBITDA up 75% to $170.4 million. The company raised full-year Adjusted EBITDA guidance by $50 millio...
- Adjusted EBITDA surged 75% year-over-year to $170.4 million, driven by a $16.3 million net benefit from California’s Workforce and Quality Incentive Program (WQIP). Excluding this one-time benefit, Adjusted EBITDA still grew $57 million year-over-year.
- Full-year 2026 Adjusted EBITDA guidance was raised by $50 million to a range of $605 million to $625 million, reflecting stronger-than-expected organic performance in occupancy and skilled mix.
- Revenue reached $1.42 billion, up 11% year-over-year, while same-store revenue for 284 facilities grew 8% year-over-year, highlighting the strength of the underlying operating model without acquisition tailwinds.
- +9 more takeaways
Alcon Q1 2026 Earnings Call - UNITY and TRYPTYR Drive Share Gains Amidst Market Headwinds
Alcon delivered a solid first quarter, with constant-currency sales rising 6% to $2.7 billion, driven by strong adoption of new products and pricing power. The surgical franchise grew 6%, led by a 23%...
- Constant-currency sales grew 6% to $2.7 billion, with surgical up 6%, vision care up 6%, and ocular health up 10%.
- UNITY equipment sales surged 23% to $253 million, acting as a catalyst for consumable pull-through and installed base expansion.
- PanOptix Pro drove nearly two share points of growth in the U.S. presbyopia-correcting IOL category, with international launches in Australia, Japan, Korea, and Europe underway.
- +13 more takeaways
First Majestic Silver Q1 2026 Earnings Call - Record Revenue and Expanding Margins Drive Cash Flow Surge
First Majestic Silver delivered a record-breaking first quarter, generating $477 million in revenue, a 95% year-over-year increase, fueled by soaring silver prices and disciplined operational executio...
- Record Q1 revenue of $477 million, up 95% year-over-year, driven by an average realized silver price of $86.35 per ounce.
- Silver production hit 3.5 million ounces, representing 26% of the full-year midpoint guidance, while gold production reached 28% of guidance.
- Operating margins expanded nearly fourfold to $52 per ounce, up from $13 per ounce in Q1 2025, as price gains outpaced cost increases.
- +7 more takeaways
Recursion Pharmaceuticals Q2 2024 Earnings Call - Five Programs with Clear Catalysts and 30% OpEx Cut
Recursion Pharmaceuticals is moving from AI promise to clinical proof, anchored by five wholly owned programs with defined inflection points over the next 12 to 18 months. The company delivered early ...
- Recursion has five wholly owned programs with clear clinical inflection points expected over the next 12 to 18 months, creating a consistent cadence of catalysts.
- REC-1245, an RBM39 degrader for solid tumors and lymphoma, showed a well-tolerated safety profile with no dose-limiting toxicities and confirmed target engagement in early Phase I data.
- REC-4539, an LSD1 inhibitor designed to mitigate on-target thrombocytopenia, has dosed its first patient in a Phase I trial for solid tumors including small cell lung cancer.
- +7 more takeaways
Imunon Q1 2026 Earnings Call - OVATION 3 Enrollment Gains Traction as Management Targets Non-Dilutive Financing
Imunon (IMNN) reported first-quarter 2026 results that underscore a strategic pivot toward capital preservation as it pushes its pivotal OVATION 3 trial for IMNN-101 into full gear. Management highlig...
- OVATION 3 Enrollment Pace: Patient enrollment for the pivotal Phase III trial is tracking ahead of internal monthly targets, with management projecting approximately 80 patients enrolled by the end of Q1 2027.
- Full Enrollment Timeline: The company has set a definitive target to fully enroll the 500-patient OVATION 3 trial by the first quarter of 2029.
- Phase II Data Strength: The final analysis of the completed OVATION 2 Phase II study showed a clinically meaningful 14.7-month median overall survival benefit for IMNN-101 combined with standard of care chemotherapy.
- +7 more takeaways
Broadwind {Q1} {2026} Earnings Call - Strategic Pivot to Power Generation and Defense Drives Record Backlogs and Margin Expansion
Broadwind is executing a decisive exit from its policy-dependent wind tower business, completing the divestiture of its Abilene facility by Q3 2026. This strategic pivot redirects capital and manufact...
- Broadwind is accelerating its exit from the wind tower market, with the sale of its Abilene facility closing post-Q1 2026 and all wind-related operations winding down by Q3 2026.
- Industrial Solutions reported record orders of $14.6 million in Q1, driving a new backlog high of $43.3 million, up more than $5 million from the previous peak.
- Gearing segment orders surged 66% year-over-year to $13.2 million, supported by a $30.5 million backlog, fueled by power generation and natural gas turbine demand.
- +7 more takeaways
Consolidated Water Company Q1 2026 Earnings Call - Manufacturing Revenue Collapses, Services Momentum Builds
Consolidated Water Company reported an 11% year-over-year revenue decline in Q1 2026, driven by a 76% collapse in manufacturing revenue and a 10.2% drop in retail volume due to unseasonably wet weathe...
- Total revenue fell 11% to $30 million year-over-year, dragged down by a $4.4 million plunge in manufacturing and an $834,000 decline in retail.
- Manufacturing revenue cratered 76% to $1.4 million due to unfavorable timing of purchase orders and a lack of large new contracts compared to the record-breaking 2025.
- Retail water sales in Grand Cayman dropped 10.2% in volume, directly correlated with significantly higher rainfall in Q1 2026 compared to the drought-like conditions of Q1 2025.
- +7 more takeaways
Stellus Capital Investment Corporation Q1 2026 Earnings Call - Dividend Sustainability Under Pressure as Non-Accruals Rise
Stellus Capital Investment Corporation reported a mixed first quarter, with core net investment income of $0.27 per share offset by a $0.28 per share decline in net asset value driven by dividend spil...
- Core net investment income came in at $0.27 per share, while GAAP NII was $0.26 per share. Total realized income reached $0.29 per share after a $750,000 gain on one equity position.
- Net asset value fell $0.28 per share, split between $0.08 from dividend spillover payments exceeding earnings and $0.20 in realized and unrealized losses tied to two debt investments.
- The portfolio closed at $990 million fair value across 116 companies, down from $1.01 billion in Q4 2025, with 99% of loans secured and 92% floating rate.
- +7 more takeaways
Intercorp Financial Services Q1 2026 Earnings Call - Record Net Income and Strategic InFinance Acquisition Drive Growth
Intercorp Financial Services delivered a record-breaking first quarter in 2026, with net income surging 35% year-over-year to PEN 602 million and return on equity climbing to 19.4%. The results were a...
- Record quarterly net income reached PEN 602 million, a 35% year-over-year increase, with return on equity hitting 19.4%.
- Higher-yielding loans grew 9% year-over-year, driven by strong performance in mortgages, mid-sized companies, and small business segments.
- Risk-adjusted net interest margin expanded 90 basis points year-over-year to 4.2%, supported by a record-low cost of risk of 1.4%.
- +7 more takeaways